Metformin is often framed as a longevity shortcut, but evidence strength differs by population and endpoint. It has a clear role in glycemic management and possible preventive value in selected profiles, but it is not a universal anti-aging default. Here's the balanced evidence read.[2]
Where metformin evidence is strongest
Evidence is strongest in type 2 diabetes and insulin-resistant populations where glycemic and cardiometabolic benefits are clear.
Off-label prevention discussions should still be anchored to baseline risk and lab profile rather than trend-chasing.
Key caveats in longevity framing
Longevity endpoint data is not equivalent to short-term biomarker change. Surrogate improvements do not always translate into broad lifespan effects.
GI side effects and B12 depletion risk are practical adherence and safety considerations.
How clinicians decide fit
Decision quality improves when fasting insulin, A1c, weight trajectory, and lifestyle adherence are reviewed first.
Metformin is usually layered into a broader metabolic plan, not used as a replacement for training and nutrition execution.